Alprostadil (Caverject/MUSE): What to Expect, Week-by-Week First Month

How Alprostadil Works and Why It Bypasses PDE5 Failure

Alprostadil is synthetic prostaglandin E1 (PGE1). Rather than blocking phosphodiesterase-5 as sildenafil and tadalafil do, alprostadil binds EP2 and EP3 receptors on cavernosal smooth-muscle cells, directly elevating cyclic AMP and triggering smooth-muscle relaxation, arterial dilation, and venous outflow restriction. This cAMP-dependent pathway is intact in most men who fail oral PDE5 inhibitors, which explains its utility in that population. 1

Why PDE5 Failures Still Respond

PDE5 inhibitors require endogenous nitric oxide release triggered by sexual stimulation. Nerve damage (post-prostatectomy), severe arterial insufficiency, or low testosterone can reduce that NO signal below the threshold needed to activate the cGMP cascade. Alprostadil circumvents that requirement entirely. 2

Caverject vs. MUSE: Two Delivery Systems

Caverject (alprostadil sterile powder, Pfizer) is injected directly into the corpus cavernosum using a 27 to 30 gauge needle. MUSE (Medicated Urethral System for Erection, Meda Pharmaceuticals) delivers a small pellet into the urethra via a plastic applicator; absorption occurs across the urethral mucosa into the corpora. Intracavernosal delivery achieves plasma and tissue concentrations approximately 10-fold higher per microgram than intraurethral delivery, so MUSE doses are correspondingly larger. 3

Before Your First Dose: Clinic Orientation (Days 1 to 3)

No patient should self-inject or self-administer MUSE at home before a supervised in-clinic titration. The FDA prescribing information for Caverject specifies that "the first dose must be given in the physician's office" to identify the lowest effective dose, monitor for prolonged erection, and train on proper injection technique. 4

What Happens During Clinic Titration

A clinician injects an initial dose of 2.5 mcg (neurogenic/psychogenic ED) or 2.5 to 5 mcg (vasculogenic ED). Erection quality is graded on a scale from 0 (no response) to 4 (fully rigid). Blood pressure is checked at 30 and 60 minutes. If the erection persists beyond 60 minutes, a dose-reduction note is made; if no response occurs, an upward titration of 5 mcg increments follows at a subsequent visit, separated by at least 24 hours. 4

For MUSE, the starting dose is 125 mcg or 250 mcg. The patient voids first to wet the urethra, then inserts the applicator 3.2 cm and depresses the plunger. The clinic monitors for symptomatic hypotension (MUSE causes systemic vasodilation more readily than injection) and syncope. 5

Training on Self-Injection Technique

Injection technique errors are the leading preventable cause of poor response and fibrosis. The needle enters at the 2 or 10 o'clock position of the mid-shaft, avoiding the dorsal neurovascular bundle and the urethra at 6 o'clock. Pressing the injection site for 2 to 5 minutes after withdrawal reduces hematoma risk. A 2018 audit by Brant et al. Found that inadequate injection training correlated with a 3-fold higher rate of corporal fibrosis over 24 months. 6

Week 1: The First Home Use

After successful clinic titration, week 1 centers on replicating that dose at home. Most men feel apprehensive about self-injection; that is normal. The technique becomes routine for most patients within two to four uses.

Expected Erection Characteristics

A correctly dosed response begins within 5 to 15 minutes after injection or 8 to 20 minutes after MUSE insertion. 7 Erection quality at the titrated dose should reach Grade 3 (sufficient for penetration) or Grade 4 (fully rigid). Duration varies by dose and individual vascular response, typically 30 to 60 minutes for intracavernosal alprostadil at 10 to 20 mcg. 7

Local Pain and What Is Normal

Penile aching is the most reported side effect. In Linet et al. (NEJM 1996, N=683), penile pain occurred in 37% of injection visits. 7 The pain is usually mild-to-moderate, peaks near erection onset, and resolves as the erection subsides. Burning at the MUSE insertion site occurs in up to 36% of users. 5 Neither symptom requires dose reduction unless rated severe (7 or above on a 0 to 10 VAS scale) or lasting beyond the erection itself.

When to Call the Clinic Immediately

An erection lasting more than 4 hours (priapism) is a urological emergency requiring prompt intervention to prevent permanent ischemic injury. Patients should have the clinic's after-hours number visible before the first home dose. Priapism risk at correctly titrated doses is below 1%, but the absolute instruction is clear: go to an emergency department if the erection has not resolved by the 4-hour mark. 8

Week 2: Dose Refinement and Pattern Recognition

By week 2, most patients have completed two to four doses. The key task is identifying the minimum effective dose that produces a Grade 3 to 4 erection without exceeding 60 minutes of duration.

Upward Titration Criteria

If the week-1 home dose produced only a Grade 1 to 2 response, contact the prescribing clinician before increasing. Self-titrating upward without guidance is the most common cause of overdose-related priapism. The FDA label allows dose increments of 5 to 10 mcg after documented inadequate response, up to a ceiling of 40 mcg per dose. 4

Psychological Adaptation

Injection anxiety typically peaks in week 1 and declines substantially by week 3 to 4. A 2014 prospective study (N=114) by Kratzik et al. Found that patient-reported sexual satisfaction scores rose from 4.1 to 6.8 out of 10 between first and sixth use, driven largely by reduced anxiety rather than any pharmacological change. 9

Erection quality is partly influenced by mental state. Some men report that the erection at home (with a partner) is subjectively better than the clinic erection at the same dose, which reflects reduced sympathetic tone in a familiar environment. 9

Tracking a Dose Log

Keep a written or app-based dose log recording: date, dose in mcg, onset time, erection grade (0 to 4), duration in minutes, pain score (0 to 10), and any complications. This log is the single most useful tool for the follow-up visit at the end of month 1. Clinicians use it to fine-tune the dose and identify early fibrosis signals (new penile curvature or a palpable nodule). 6

Week 3: Optimizing the Routine

Week 3 is where dose and technique stabilize for most patients. The focus shifts from "will this work?" to "how do I integrate this into my sex life?"

Injection Site Rotation

Alternating injection sides (left corpus for one dose, right for the next) distributes mechanical micro-trauma across a wider area, reducing focal fibrosis risk. The American Urological Association (AUA) 2018 Erectile Dysfunction Guideline states that "patients should be counseled to rotate injection sites to minimize the risk of corporeal fibrosis." 10

Storage and Reconstitution Reminders

Caverject powder must be reconstituted with the supplied diluent immediately before use. Reconstituted solution is stable for only 24 hours at room temperature or up to 3 months refrigerated in the dual-chamber syringe form (Caverject Impulse). Unused MUSE suppositories should be refrigerated and used before the printed expiration date. 4

Combining MUSE with a Constriction Band

A venous constriction band placed at the base of the penis after MUSE insertion doubles the rate of adequate erections in randomized data. Padma-Nathan et al. (Urology 1997, N=1,511) reported that MUSE plus a band achieved a 64.9% in-clinic response vs. 43.1% for MUSE alone. 11 The band should be removed within 30 minutes to avoid ischemia.

Week 4: First Follow-Up Appointment and Long-Term Planning

The 4-week follow-up visit is the standard checkpoint for alprostadil therapy. Bring the dose log. The clinician checks the penis for nodules (early Peyronie's plaque), adjusts the dose, and confirms the frequency limit of no more than 3 injections per week with at least 24 hours between doses. 4

Efficacy Benchmarks at One Month

In Linet et al. (NEJM 1996, N=683), 94.8% of alprostadil-treated men achieved at least one successful home intercourse during the study, versus 20.7% in the placebo group (P<0.001). 7 The MUSE key trial (Padma-Nathan, NEJM 1997, N=1,511) reported that 64.9% of men achieved an erection sufficient for intercourse at home after dose optimization. 11 Men who have not achieved a Grade 3 response by week 4 may need further titration, a switch between delivery systems, or combination therapy.

Combination Therapy Considerations

For men with a partial response to alprostadil alone, combination intracavernosal therapy (the "Trimix" formulation of alprostadil + phentolamine + papaverine) may be offered. A systematic review by Habous et al. (2017) found Trimix superior to alprostadil monotherapy in vasculogenic ED, with response rates exceeding 90% in some cohorts. 12 This decision requires a separate prescribing visit.

Long-Term Safety: Fibrosis and Peyronie's Disease Risk

Corporal fibrosis is the major long-term concern with intracavernosal therapy. The AUA Erectile Dysfunction Guideline reports a fibrosis incidence of approximately 2 to 7% over 2 years with proper technique, rising to higher rates with poor rotation or frequent dosing above the recommended ceiling. 10 Any new penile curvature, shortening, or palpable plaque should prompt an urgent clinic visit. Early Peyronie's disease may be managed with intralesional collagenase clostridium histolyticum (Xiaflex) if caught within 12 months of symptom onset. 13

Side Effects: Full Spectrum and Management

Understanding the full side-effect profile prevents unnecessary discontinuation during the titration phase.

Penile and Local Effects

Penile pain (37% incidence in Linet et al.) is the most common reason for discontinuation. 7 Mild pain rarely justifies stopping therapy; adjusting the dose downward by 2.5 to 5 mcg often reduces it substantially. Hematoma at the injection site occurs in roughly 3% of cases and typically resolves within 1 to 2 weeks with conservative management. 14

Prolonged erection (defined as lasting 2 to 6 hours without stimulation) occurs in roughly 3 to 5% of new users before the optimal dose is established. Sustained erection beyond 6 hours constitutes ischemic priapism, which requires intracavernosal aspiration and phenylephrine irrigation. 8 After priapism is resolved, the dose must be reduced by at least 50% before any future use.

Systemic Effects

Systemic absorption from intracavernosal alprostadil is low (less than 2% reaches systemic circulation), so hemodynamic effects are generally minor. 15 MUSE carries a higher systemic absorption and causes dizziness in up to 3.3% and hypotension in 1.4% of patients in key trial data. 11 Patients with pre-existing hypotension or those on antihypertensives should sit for 10 minutes after MUSE insertion before standing.

Urethral pain, minor urethral bleeding, and testicular aching occur in up to 5% of MUSE users and usually resolve without intervention. 5

Special Populations: Post-Prostatectomy, Diabetes, and Cardiovascular Disease

Post-Prostatectomy ED

Penile rehabilitation after radical prostatectomy (RP) is one of the most common indications for alprostadil. A randomized trial by Montorsi et al. (Urology 1997, N=30) showed that early intracavernosal alprostadil three times weekly after nerve-sparing RP significantly improved rates of spontaneous erection recovery at 6 months (67% vs. 20% with no rehabilitation). 16 The proposed mechanism is maintaining oxygenated blood flow to prevent smooth-muscle apoptosis and cavernosal fibrosis during the neuropraxia recovery period. 16

Diabetic ED

Men with diabetes-associated ED frequently have both neuropathic and vasculogenic components that blunt PDE5 inhibitor efficacy. A dedicated analysis of diabetic subgroups in alprostadil trials found response rates of 60 to 70%, broadly consistent with the overall population but requiring slightly higher mean doses (mean 17.6 mcg vs. 13.4 mcg in non-diabetic men). 14 Glycemic control does not need to meet a specific threshold before initiating alprostadil, but HbA1c above 9% is associated with higher rates of corporal fibrosis. 10

Cardiovascular Considerations

Sexual activity with a partner is roughly equivalent to climbing two flights of stairs, requiring a metabolic equivalent of 3 to 4 METs. The Princeton III Consensus (2012) advises that men who can perform moderate-intensity activity without symptoms are candidates for any ED pharmacotherapy. 17 Alprostadil does not interact with nitrates (unlike PDE5 inhibitors), making it the preferred ED treatment in men who require nitrate therapy for angina. 4

What the Evidence Says About Satisfaction and Continuation

Long-term adherence with intracavernosal alprostadil is modest but clinically meaningful. A 3-year follow-up analysis by Sundaram et al. Found that 68% of men who completed titration continued therapy at 12 months, dropping to 51% at 36 months. 18 The primary reasons for discontinuation were fear of needles, penile pain, and partner dissatisfaction with the spontaneity loss. Structured patient education and partner counseling at months 1 and 3 significantly improved 12-month continuation rates in a prospective audit. 9

Partner involvement is a documented predictor of continuation. In the Sundaram cohort, 82% of men whose partners attended at least one counseling session remained on therapy at 12 months versus 54% of men whose partners were not involved. 18

MUSE adherence is lower than injection in head-to-head comparisons, driven by a higher rate of inadequate erection at home versus the clinical setting. The home-use success rate for MUSE in the Padma-Nathan key trial was 64.9%, but a real-world audit by Porst (1996) placed home-use success closer to 40 to 50% without a constriction band. 3

Practical Summary: Week-by-Week Reference Table

| Week | Primary Goal | Key Action | |------|-------------|------------| | Pre-start (Days 1 to 3) | Supervised titration | Clinic injection, dose identified, priapism protocol reviewed | | Week 1 | First home use | Replicate clinic dose; track pain and duration | | Week 2 | Dose refinement | Report inadequate response; adjust if needed | | Week 3 | Routine integration | Rotate injection sites; reinforce storage rules | | Week 4 | Follow-up visit | Bring dose log; fibrosis check; long-term plan set |